{
    "2018-03-23": [
        [
            {
                "time": "2018-03-22",
                "original_text": "AbbVie Stock Falls on Weak Lung Cancer Study Outcome",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "lung cancer",
                        "study outcome"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "AbbVie: Biggest Loss in the S&P 500 on March 22",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "S&P 500",
                        "loss"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "cancer drug",
                        "disappointing results",
                        "$5.8 billion deal"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "Today’s Research Reports on Stocks to Watch: AbbVie and Pfizer",
                "features": {
                    "keywords": [
                        "research reports",
                        "AbbVie",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "AbbVie’s latest trial data was probably worse than it looked",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "trial data",
                        "worse"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "Is The AbbVie Dip A Buying Opportunity?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "dip",
                        "buying opportunity"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "Asian shares slump on fears of trade war between US, China",
                "features": {
                    "keywords": [
                        "Asian shares",
                        "trade war",
                        "US",
                        "China"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "global markets"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-22",
                "original_text": "Is It Game Over for AbbVie's Promising Cancer Drug?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "cancer drug",
                        "promising"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}